Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids Emil BujakFrancesca PrettoDario Neri PRECLINICAL STUDIES 19 May 2015 Pages: 791 - 800
The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines Federica TonissiLaura LattanzioOrnella Garrone PRECLINICAL STUDIES 07 May 2015 Pages: 801 - 809
Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency Xinmei XieLin WangXiaobin Pang PRECLINICAL STUDIES 09 May 2015 Pages: 810 - 815
In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis Sarah SchottSonia ValletChristian Busch PRECLINICAL STUDIES 20 May 2015 Pages: 816 - 826
Amidation inhibitors 4-phenyl-3-butenoic acid and 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid methyl ester are novel HDAC inhibitors with anti-tumorigenic properties Amna AliTimothy J. BurnsDiane F. Matesic PRECLINICAL STUDIES 13 June 2015 Pages: 827 - 834
Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs Ekaterina Schreiber-BrynzakErik KlapprothBernhard K. Keppler PRECLINICAL STUDIES 21 June 2015 Pages: 835 - 847
Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer Philippe ColleryAhmed MohsenJean d’Angelo PRECLINICAL STUDIES Open access 26 June 2015 Pages: 848 - 860
Cytotoxicity of anthraquinones from the roots of Pentas schimperi towards multi-factorial drug-resistant cancer cells Victor KueteArno R. Nanfack DonfackThomas Efferth PRECLINICAL STUDIES 27 June 2015 Pages: 861 - 869
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies Guillermo Garcia-ManeroRaoul TibesHanna Jean Khoury PHASE I STUDIES 02 May 2015 Pages: 870 - 880
Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer Hidehito HorinouchiNoboru YamamotoTomohide Tamura PHASE I STUDIES Open access 01 May 2015 Pages: 881 - 889
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer Zahi MitriCansu KarakasStacy Moulder PHASE I STUDIES 07 May 2015 Pages: 890 - 894
Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT) Joanne W. ChiuKelvin ChanAlbiruni R. Abdul Razak PHASE I STUDIES 05 May 2015 Pages: 895 - 900
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors Mark J. RatainDavid GearyBernardo Miguel-Lillo PHASE I STUDIES 08 May 2015 Pages: 901 - 910
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver Rabih SaidRazelle KurzrockApostolia M. Tsimberidou PHASE I STUDIES 21 May 2015 Pages: 911 - 920
Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors Khanh DoGiovanna SperanzaShivaani Kummar PHASE I STUDIES 18 June 2015 Pages: 921 - 930
Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib Nagdeep GiriJoanna C. MastersCarlo Bello PHASE I STUDIES 06 June 2015 Pages: 931 - 941
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose Karthik VenkatakrishnanTae Min KimWon Seog Kim PHASE I STUDIES 19 June 2015 Pages: 942 - 953
A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study Norisuke NakayamaAtsushi SatoThe Tokyo Cooperative Oncology Group, Tokyo, Japan PHASE II STUDIES 05 May 2015 Pages: 954 - 962
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study Katrina S. PedersenGeorge P. KimRobert R. McWilliams PHASE II STUDIES 08 May 2015 Pages: 963 - 968
A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195 B. J. EiglS. NorthK. N. Chi PHASE II STUDIES 19 May 2015 Pages: 969 - 976
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer S. M. ReddyS. KopetzC. Eng PHASE II STUDIES 12 June 2015 Pages: 977 - 984
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079) B. B. Y. MaB. C. GohA. T. C. Chan PHASE II STUDIES 19 June 2015 Pages: 985 - 991
Targeting the plasma membrane of neoplastic cells through alkylation: a novel approach to cancer chemotherapy Matthew TrendowskiThomas P. Fondy REVIEW Open access 23 June 2015 Pages: 992 - 1001